Considering Amneal Pharmaceuticals Inc. (AMRX) as a potential investment: What Should You Do?

After finishing at $2.43 in the prior trading day, Amneal Pharmaceuticals Inc. (NYSE: AMRX) closed at $2.54, up 4.53%. In other words, the price has increased by $+0.1100 from its previous closing price. On the day, 2166702 shares were traded. AMRX stock price reached its highest trading level at $2.5900 during the session, while it also had its lowest trading level at $2.4300.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



Our goal is to gain a better understanding of AMRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.10. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.70. In the meantime, Its Debt-to-Equity ratio is 9.42 whereas as Long-Term Debt/Eq ratio is at 9.10.

Upgrades & Downgrades

On March 08, 2021, Goldman Upgraded its rating to Buy which previously was Sell and also upped its target price recommendation from $4 to $6.50.

Guggenheim Upgraded its Neutral to Buy on December 14, 2020, while the target price for the stock was maintained at $5.50.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 12 when TPG GP A, LLC sold 3,884,600 shares for $2.34 per share. The transaction valued at 9,095,402 led to the insider holds 12,328,767 shares of the business.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.35 while its Price-to-Book (P/B) ratio in mrq is 1.30.

Stock Price History:

Over the past 52 weeks, AMRX has reached a high of $4.98, while it has fallen to a 52-week low of $1.95. The 50-Day Moving Average of the stock is 2.2504, while the 200-Day Moving Average is calculated to be 2.7233.

Shares Statistics:

The stock has traded on average 1.23M shares per day over the past 3-months and 1.36M shares per day over the last 10 days, according to various share statistics. A total of 151.39M shares are outstanding, with a floating share count of 118.88M. Insiders hold about 0.10% of the company’s shares, while institutions hold 66.90% stake in the company. Shares short for AMRX as of Oct 13, 2022 were 4.82M with a Short Ratio of 8.24M, compared to 4.6M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.18% and a Short% of Float of 4.69%.

Earnings Estimates

Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of $0.18 for the current quarter, with a high estimate of $0.2 and a low estimate of $0.14, while EPS last year was $0.21. The consensus estimate for the next quarter is $0.2, with high estimates of $0.23 and low estimates of $0.14.

Analysts are recommending an EPS of between $0.72 and $0.59 for the fiscal current year, implying an average EPS of $0.68. EPS for the following year is $0.82, with 7 analysts recommending between $0.92 and $0.73.

Revenue Estimates

A total of 7 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $2.22B, while the lowest revenue estimate was $2.16B, resulting in an average revenue estimate of $2.2B. In the same quarter a year ago, actual revenue was $2.09B, up 5.10% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $2.31B in the next fiscal year. The high estimate is $2.35B and the low estimate is $2.26B. The average revenue growth estimate for next year is up 5.00% from the average revenue estimate for this year.